Luijten Maartje M W, van Weelden Willem Jan, de Kroon Cornelis D, Pijnenborg Johanna M A, van Gent Mignon D J M
Radboudumc, afd. Gynaecologie, Nijmegen.
Contact: Maartje M.W. Luijten (
Ned Tijdschr Geneeskd. 2021 Nov 25;165:D5765.
The incidence of endometrial carcinoma (EC) is rising worldwide due to an increased life expectancy and obesity. Approximately 2% of patients with EC is under the age of 45. Because the incidence is also rising in young women, there is a clinical need for safe fertility sparing alternative treatments.
A 32-year-old women was diagnosed with low-grade endometrioid EC. Hysteroscopic tumour resection and progestin treatment resulted in complete tumour regression. The patient became pregnant through in vitro fertilisation (IVF).
This case illustrates that fertility sparing treatment, with oral progestin treatment is an alternative treatment option in selected young women with low grade, early stage endometrial carcinoma to achieve pregnancy. This treatment is internationally accepted.
由于预期寿命延长和肥胖，子宫内膜癌（EC）在全球的发病率正在上升。约2%的子宫内膜癌患者年龄在45岁以下。由于年轻女性中的发病率也在上升，临床上需要安全的保留生育功能的替代治疗方法。
一名32岁女性被诊断为低级别子宫内膜样癌。宫腔镜肿瘤切除术和孕激素治疗导致肿瘤完全消退。该患者通过体外受精（IVF）怀孕。
本病例表明，对于部分低级别、早期子宫内膜癌的年轻女性，口服孕激素进行保留生育功能治疗是实现妊娠的一种替代治疗选择。这种治疗方法已得到国际认可。
